Halogen-Containing mRNA Cap Compounds for High Capping Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for chemically modifying the cap structure of mRNA to enhance translation efficiency and reduce immunogenicity are inadequate, particularly in terms of capping efficiency and cellular translation expression.
Innovation Solution
A halogen-containing compound with modified or unmodified 7-methylguanine bases and a halogen substituent at the 2' position of the nucleoside is used to cap the 5' end of mRNA, providing high capping rates and efficient in vitro and cellular translation expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current chemical modification methods are used to modify cap structure, then translation efficiency enhancement is achieved, but capping efficiency is insufficient
Solution Approach 1:
The patent introduces halogen-containing compounds (Formula I) with specific structural parameters (R0-R7 groups, N01-N04 positions, J1-J5 bases) to modify the cap structure. By changing chemical parameters such as halogen substitution at the 2' position and various R group configurations, the invention achieves both high capping efficiency (>90%) and high translation efficiency simultaneously, resolving the contradiction between capping efficiency and translation efficiency.
2Productivity
If cap structure is chemically modified to enhance translation efficiency, then protein translation is improved, but immunogenicity increases
Solution Approach 1:
The patent applies local quality modification by introducing specific halogen-containing groups at particular positions (R0-R7) of the cap structure while maintaining other regions unchanged. The halogen substitution at the 2' position and specific R group configurations provide localized chemical modification that enhances translation efficiency while the overall cap structure remains recognized by cellular machinery, thereby reducing immunogenicity compared to more extensive modifications.
3Productivity
If halogen-containing compound is used for capping, then capping rate increases, but structural complexity increases
Solution Approach 1:
The patent achieves high capping rates with relatively simple structural changes by modifying specific parameters of the cap structure (Formula I). The halogen substitution at the 2' position and systematic variation of R groups (R0-R7) provide a structured approach to complexity management, where each parameter change is purposeful and targeted, avoiding unnecessary structural complexity while achieving >90% capping rates.
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention provides a halogen-containing compound for capping 5' end of nucleic acid and a use thereof. The compound is shown in the following formula (I). The present invention also provides uses and effects of the compound in nucleic acid transcription and expression.